Ignota Labs

We’re delighted that four Cambridge companies have been named finalists in the Royal Society of Chemistry’s Emerging Technologies Competition 2024! 💡 These awards showcase the exceptional chemistry-led technologies being developed by 24 forward-thinking organizations across the UK. It’s amazing to see our friends and colleagues receiving well-deserved recognition for their fantastic work in the energy, environment and health categories. Discover more about shortlisted companies below. Energy finalists:  H2Upgrade and Ewa Marek Environment finalists: Protonera Health finalists:  Ignota Labs  Vector Bioscience Cambridge Good luck to everyone at the Final on 4th July! Find out more about the Emerging Technologies 2024 Competition here: https://lnkd.in/gHce_G4p #RSCEmergingTech #UKInnovation #Science #Technology

Please give a warm welcome to Cristina Marson, another intern joining us this Summer! 🎉 Cristina studied Biomedical Sciences at University of Oxford before pursuing an MPhil in Bioscience Enterprise at University of Cambridge. She has experience in life sciences consulting and has held several business intern roles at various startups. Cristina will be joining us for two months as a full-time business intern and is excited to continue expanding her experience in this field. She will be working on several business development projects ranging from marketing to strategic asset assessment and investor relations. We look forward to seeing her apply her skills and bring her enthusiasm to the team! #Internship #SummerInterns #BiomedicalScience #LifeSciencesConsulting #BusinessDevelopment #Marketing #StrategicAssessment #InvestorRelations #CambridgeAlumni #OxfordAlumni #LifeSciences #StartupExperience #TeamGrowth #InternshipExperience #BusinessIntern #NewTalent

🙏 Thank you OBN (UK) Ltd for the chance to present at #bioseedsummer2024 🏙️ It is my first time in #onecanadasquare at the heart of Canary Wharf - mad to think they are putting labs up here! 🗣️ I told a room full of investors and entrepreneurs about our unique asset salvaging model and the progress we have made in the last 6 months. 🙌 Great to see people I haven’t spoken to for a while coming over and congratulating us on our progress and milestones! #biotech #safety #fundraising #assetturnaround #aidrugdiscovery #drugfailures #entrepreneurship

So excited to have FOUR new starters joining us in the near future including our three amazing interns; two on the tech side (bringing us up from 50/50 to a majority female tech team 🎉 ) and one on the business and fundraising side. Stay tuned for the rest of their profiles!

Ignota Labs is proud of our dedication to offering internships that provide a holistic experience of working in a startup. We are excited to announce that we have three talented interns joining us this summer. To introduce them, we are launching a series of posts, starting with Katie Beckwith. Katie is a third year PhD candidate on the SynTech CDT at the University of Cambridge focusing on explainable AI in chemistry, with a focus on toxicology, under the supervision of Professor Jonathan Goodman. Prior to this she completed a MChem in Medicinal Chemistry at the University of Leeds, where she first investigated the use of AI and machine learning in chemistry during her masters dissertation; which focused on using machine learning and local chemical descriptors for the prediction of nucleophilicity parameters. Katie will be joining Ignota Labs for the summer and will be focusing on investigating both model specific and agnostic explainability techniques to determine which techniques produce reliable toxicophores for a given endpoint. #Internship #StartupLife #AI #MachineLearning #Chemistry #Toxicology #ExplainableAI #STEM #WomenInSTEM #CareerDevelopment #PhD #Research #Innovation

One week to go! Ignota Labs is looking forward to participating in the Cambridge Wide Open Day at The Bradfield Centre venue, 12th June from 11 am - 3 pm. Come see our CEO Sam Windsor at 1:20 pm to talk about our innovations in solving safety issues in drug discovery.

One week to go! Ignota Labs is looking forward to participating in the Cambridge Wide Open Day at The Bradfield Centre venue, 12th June from 11 am - 3 pm. Come see our CEO Sam Windsor at 1:20 pm to talk about our innovations in solving safety issues in drug discovery.

We are proud to be a Milner Therapeutics Institute affiliated company! Ignota Labs is excited to join this rich ecosystem, which blends expertise from the brightest and best across academia and industry #announcement #innovation #collaboration #milnerinstitute

Our Affiliated Company network now includes 66 organisations that bring diverse expertise and resource to the Milner community? We are delighted to have recently welcomed the following new affiliated companies to our network: 🌻 AIGENDRUG Co., Ltd. is an AI drug discovery research company that provides a new way of exploring the chemical, genetic, and disease space with cutting edge AI technologies. Aigendrug launched its AI platform DrugVLAB v1 in April 2024, featuring ChemGen, ChemMining, ChemTox, ChemResponse, ChemTune, and ChemProtac. 🌻 OmicsChart (Techstars'23) is developing a software solution for translational cancer research, enabling rapid access and analysis of harmonized biomarker data for 35 cancer indications through domain-specific AI and ML. Their solution reduces data acquisition and analysis time by 150 times compared to current practices. OmicsChart is supported by industry leaders such as the Debiopharm Innovation Fund, Techstars, and Merck. 🌻 Ignota Labs is an AI-driven drug discovery company specialising in the mechanistic understanding of safety to revitalise distressed pharmaceutical assets. They partner and in-license drugs that biotechs have abandoned due to safety concerns, creating new value from drugs that were otherwise dead. 🌻 Pharmidex is a UK-based contract research organisation, founded in 2002, providing high quality, cost-effective and rapid solutions to clients. Their services include in vitro ADME, drug metabolism and pharmacokinetics (DMPK), bioanalysis (non-GLP, GLP/GCP), toxicology (non-GLP, GLP) and histology/clinical chemistry/ haematology. Pharmidex also offers in silico modelling and efficacy models supporting oncology, CNS, respiratory, stroke, autoimmune and metabolic disease programmes. 🌻 Selleck Chemicals LLC are the second-largest biocompound vendor in the world and specialize in inhibitors for in vivo and in vitro application, compound libraries, therapeutics and in vivo antibodies, and bioreagents. Their products have been cited in numerous publications and have been trusted by researchers around the globe 🌻 Synexa Life Sciences is a global provider of biomarker and bioanalytical services, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays. Synexa's main areas of expertise include biomarker identification and development, clinical bioanalysis, soluble biomarker analysis (utilising MSD, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry and ELISpot) and genomic services to support clinical trials and translational studies.

Exciting News! 🎉 We are thrilled to announce that out of 140 applicants, we have been shortlisted for the finals of the Royal Society of Chemistry Emerging Technologies competition! This recognition is a testament to the hard work and dedication of our amazing team in continually pushing the boundaries of technology and science. We are honoured to be among the top contenders in this prestigious competition and look forward to showcasing our innovative technology on the 4th July. #RSC #EmergingTechnologies #Innovation #Science #Technology #ProudMoment #TeamWork